ResearcherNanjing University of Chinese MedicineActive in the last 2 years
Lina Song
Matched on ORCID iD 0000-0001-6547-335X; OpenAlex author ID A5100674615. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper
Papers 8
- Multimodal Imaging-Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine. Co-author DOI 10.1002/adhm.202302195↗
- Exploring the key genetic association between chronic pancreatitis and pancreatic ductal adenocarcinoma through integrated bioinformatics. Co-author DOI 10.3389/fgene.2023.1115660↗
- A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics15051547↗
- Erratum: Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer [Corrigendum]. First author DOI 10.2147/ijn.s361728↗
- Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer. First author DOI 10.2147/ijn.s335588↗
- A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy. Co-author DOI 10.2217/nnm-2019-0063↗
- Plectin-1 Targeted Dual-modality Nanoparticles for Pancreatic Cancer Imaging. Co-author DOI 10.1016/j.ebiom.2018.03.008↗
- Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer. Co-author DOI 10.2147/ijn.s177993↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zhongqiu Wang · 8 shared papers, 2018–2024 · strength 1.19
- Paper A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer. DOI 10.3390/pharmaceutics15051547↗
- Paper Multimodal Imaging-Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine. DOI 10.1002/adhm.202302195↗
- Paper Exploring the key genetic association between chronic pancreatitis and pancreatic ductal adenocarcinoma through integra… DOI 10.3389/fgene.2023.1115660↗
- Shuai Ren · 6 shared papers, 2019–2024 · strength 1.04
- Paper A Gold Nanocage Probe Targeting Survivin for the Diagnosis of Pancreatic Cancer. DOI 10.3390/pharmaceutics15051547↗
- Paper Multimodal Imaging-Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine. DOI 10.1002/adhm.202302195↗
- Paper Exploring the key genetic association between chronic pancreatitis and pancreatic ductal adenocarcinoma through integra… DOI 10.3389/fgene.2023.1115660↗
- Kai Guo · 5 shared papers, 2019–2024 · strength 0.80
- Paper Multimodal Imaging-Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine. DOI 10.1002/adhm.202302195↗
- Paper Exploring the key genetic association between chronic pancreatitis and pancreatic ductal adenocarcinoma through integra… DOI 10.3389/fgene.2023.1115660↗
- Paper Erratum: Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Ca… DOI 10.2147/ijn.s361728↗
- Wenli Qiu · 3 shared papers, 2018–2024 · strength 0.38
- Paper Multimodal Imaging-Guided Photoimmunotherapy of Pancreatic Cancer by Organosilica Nanomedicine. DOI 10.1002/adhm.202302195↗
- Paper A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy. DOI 10.2217/nnm-2019-0063↗
- Paper Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer. DOI 10.2147/ijn.s177993↗
- Huifeng Zhang · 2 shared papers, 2019–2024 · strength 0.30
- Yuan Li · 1 shared paper, 2023 · strength 0.18
- Yingying Cao · 1 shared paper, 2023 · strength 0.18
- Xiao Chen · 1 shared paper, 2018 · strength 0.08
- Xiao Chen · 1 shared paper, 2018 · strength 0.08
- Yongkang Liu · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.